A p53 codon 72 polymorphism associated with breast cancer in Iranian patients

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 10, 2011, Pages 1278-1281

  Doosti, Abbas ^a   Dehkordi, Payam Ghasemi ^a   Davoudi, Noushin ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Breast cancer; Iran; P53 codon 72; Polymorphism

Indexed keywords

AGAROSE; ARGININE; PROLINE;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; DNA FRAGMENTATION; ETHNIC GROUP; GEL ELECTROPHORESIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRANIAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TUMOR SUPPRESSOR GENE;

EID: 80052975776     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP10.394     Document Type: Article

References (25)

1. Ara S, Lee PS, Hansen MF, Saya H (1990). Codon 72 polymorphism of the Tp53 gene. Nucleic Acids Res., 18: 49-61.
2. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C (2003). Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin. Cancer Res., 9: 4860-4864.
3. Buyru N, Tigli H, Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol. Rep., 10(3): 711-714.
4. Chen RH, Chang CT, Wang TY, Huang WL, Tsai CH, Tsai FJ (2008). P53 Codon 72 Proline/Arginine polymorphism and autoimmune thyroid diseases. J. Clin. Lab. Anal., 22: 321-326.
5. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33: 357-365.
6. El-Deiry WS, Tokino T, Veiculescu VE, Levy DB, Parsons R, Trent LM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993). WAF 1, a potential mediator of p53 tumor supression. Cell, 75: 817-825.
7. Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T (2002). P53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res., 8: 1192-1195.
8. Hausen HZ (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2: 342-350.
9. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005). The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res., 65: 9582-9587.
10. Kazemi M, Salehi Z, Chakosari RJ (2009). TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol. Res., 18(1): 25-30.
11. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD (1994). P53 expression in ovarian borderline tumors and stage I carcinomas. Am. J. Clin. Pathol., 102: 671-676.
12. Langerod A, Bukholm I, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL (2002). The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol. Biomarkers Prev., 11: 1684-1688.
13. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003). No evidence of correlation between p 53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann. NY Acad. Sci., 1010: 764-770.
14. Omori S, Yoshida S, Kennedy S, Negoro K, Hamana S, Barlow D, Maruo T (2004). Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. Gynecol. Investing, 11: 232-236.
15. Pich A, Margarin E, Chiusa L (2000). Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J. Clin. Oncol., 18: 2948-2956.
16. Pim D, Banks L (2004). P53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer. 108: 196-199.
17. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ (1998). P53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet, 352: 871-872.
18. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T (2001). Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogen, 22(3): 515-517.
19. Takeda A, Shimada H, Nakajima K, Suzuki T, Hori S, Hayashi H (2000). Impact of circulating p53 autoantibody monitoring after endoscopic resection in mucosal gastric cancer. Endoscopy, 32: 740-741.
20. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol., 19: 1092-1100.
21. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res., 9(3): R34.
22. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999). Prognostic significance of p53 codon 72 polymorphism in lung caecinomas. Eur. J. Cancer, 35: 226-230.
23. Wegman P, Stal O, Askmalm MS, Nordenskjold B, Rutqvist LE, Wingren S (2006). P53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet. Genomics, 16: 347-351.
24. Zhu Y, Wang J, He Q, Zhang JQ (2010). Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis. Mol. Biol. Rep., 27(2): 540-546.
25. Zubo P, Stanclova A, Kajo K, Hato J, Klobusiakov K, Visnovsk J, Danko J (2009). The p53 Codon 72 Exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Clin. Trans. Res., 76: 173-183.